Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Guiding criteria for selection of medical technologies for the “New Methods” program for managed introduction of innovations was published in Norway

08 Sep 2017

All significant innovations in Norway should undergo either national or hospital-based health technology assessment within “New Methods” framework. Guiding criteria for prioritization of topics for assessments were recently formulated by the administration of the program.

Criteria are divided into 3 segments:

  • Selection criteria: use of the method within specialized services, method in innovative, method can replace other methods, CE marking, financial responsibility for use of technology, availability of documentation for the method
  • Relevance criteria: focus on serious disease, potential benefit, high unmet need, innovativeness, high risks associated with the method, likely budget impact, available evidence, involvement of medical radiation
  • Criteria for level of potential assessment (national or hospital-based): major consequences for health care system and its budget, high-risk devices, use in screening, necessity for comprehensive health economic analysis, use of drugs in the method, companion diagnostic tests

Criteria will help Norwegian Institute of Public Health to make priority decisions about selection of topics for health technology alerts ( a form of horizon screening) for participants of the program, and prioritization of specific assessments at national and hospital levels.

Read the full document in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.